

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

POSITIVE PROFIT ALERT

This announcement is made by OrbusNeich Medical Group Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2023 (the “**FY2023**”) and the information currently available to the Board, the Group is expected to record (i) an increase in profit attributable to owners of the Company by over 100% as compared with that for the year ended December 31, 2022 (the “**FY2022**”); and (ii) an increase in adjusted profit for the year (non-HKFRS measure^{Note}) by over 50% as compared with that for FY2022.

The increase in profit for the year attributable to owners of the Company is mainly attributable to the following factors: (i) increase in gross profit arising from the increase in sales of the Group’s balloons; (ii) increase in interest income from bank deposits; and (iii) listing expenses did not recur for FY2023 as the listing of the Company was completed in 2022.

Note: Adjusted profit for the year (non-HKFRS measure) is calculated by excluding the effect of listing expenses, unwinding of interests on convertible redeemable preferred shares and share-based compensation expenses.

As the Company is still in the process of finalizing the consolidated annual results of the Group for FY2023, the information contained in this announcement is only based on a preliminary review of the unaudited consolidated management accounts of the Group for FY2023 and the information currently available to the Board, which have not been audited or reviewed by the Company's auditor or the audit committee of the Company. Shareholders and potential investors are advised to read carefully the annual results announcement of the Group for FY2023 which is expected to be released by the end of March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN

Chairman, Executive Director and Chief Executive Officer

Hong Kong, January 30, 2024

As of the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ching Chung John CHOW, Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.